Research and Development Expense of Rubius Therapeutics, Inc. from 31 Dec 2016 to 31 Dec 2022
- Taxonomy & unit
- us-gaap: USD
- Description
- The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
- Summary
-
Rubius Therapeutics, Inc. quarterly and annual Research and Development Expense in USD history and change rate from 31 Dec 2016 to 31 Dec 2022.
- Rubius Therapeutics, Inc. Research and Development Expense for the quarter ending 31 Dec 2022 was $888,000, a 98% decline year-over-year.
- Rubius Therapeutics, Inc. Research and Development Expense for the twelve months ending 31 Dec 2022 was $96,414,000, a 32% decline year-over-year.
- Rubius Therapeutics, Inc. annual Research and Development Expense for 2022 was $96,414,000, a 32% decline from 2021.
- Rubius Therapeutics, Inc. annual Research and Development Expense for 2021 was $141,587,000, a 22% increase from 2020.
- Rubius Therapeutics, Inc. annual Research and Development Expense for 2020 was $116,107,000, a 3.3% increase from 2019.
- Source SEC data
- View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)
Rubius Therapeutics, Inc. Quarterly Research and Development Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2022 | $96,414,000 | $888,000 | -$38,936,000 | -98% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2022 | $135,350,000 | $24,229,000 | -$13,785,000 | -36% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $149,135,000 | $32,998,000 | -$3,074,000 | -8.5% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $152,209,000 | $38,299,000 | +$10,622,000 | +38% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2021 | $141,587,000 | $39,824,000 | +$14,208,000 | +55% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2021 | $127,379,000 | $38,014,000 | +$9,805,000 | +35% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $117,574,000 | $36,072,000 | +$9,976,000 | +38% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2021 | $107,598,000 | $27,677,000 | -$8,509,000 | -24% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2020 | $116,107,000 | $25,616,000 | -$4,884,000 | -16% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2020 | $120,991,000 | $28,209,000 | -$5,321,000 | -16% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $126,312,000 | $26,096,000 | -$1,422,000 | -5.2% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2020 | $127,734,000 | $36,186,000 | +$15,315,000 | +73% | 01 Jan 2020 | 31 Mar 2020 | 10-Q/A | 20 Aug 2021 | 2021 | Q1 |
| Q4 2019 | $112,419,000 | $30,500,000 | +$13,961,000 | +84% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| Q3 2019 | $98,458,000 | $33,530,000 | +$19,167,000 | +133% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2019 | $79,291,000 | $27,518,000 | +$16,157,000 | +142% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2019 | $63,134,000 | $20,871,000 | +$11,365,000 | +120% | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 11 May 2020 | 2020 | Q1 |
| Q4 2018 | $51,769,000 | $16,539,000 | 01 Oct 2018 | 31 Dec 2018 | 10-K | 23 Feb 2021 | 2020 | FY | ||
| Q3 2018 | $14,363,000 | +$8,237,000 | +134% | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 14 Nov 2019 | 2019 | Q3 | |
| Q2 2018 | $11,361,000 | +$6,540,000 | +136% | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 13 Aug 2019 | 2019 | Q2 | |
| Q1 2018 | $9,506,000 | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 15 May 2019 | 2019 | Q1 | |||
| Q3 2017 | $6,126,000 | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 13 Nov 2018 | 2018 | Q3 | |||
| Q2 2017 | $4,821,000 | 01 Apr 2017 | 30 Jun 2017 | 10-Q | 31 Aug 2018 | 2018 | Q2 |
Rubius Therapeutics, Inc. Annual Research and Development Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $96,414,000 | -$45,173,000 | -32% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2021 | $141,587,000 | +$25,480,000 | +22% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2020 | $116,107,000 | +$3,688,000 | +3.3% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2019 | $112,419,000 | +$60,650,000 | +117% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| 2018 | $51,769,000 | +$30,543,000 | +144% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 23 Feb 2021 | 2020 | FY |
| 2017 | $21,226,000 | +$12,823,000 | +153% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 12 Mar 2020 | 2019 | FY |
| 2016 | $8,403,000 | 01 Jan 2016 | 31 Dec 2016 | 10-K | 28 Mar 2019 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.